Abstract:Inhibition of human norepinephrine transporter (hNET) palmitoylation by pharmacologic (2‐bromopalmitate; 2BP) and coding variant (Cys44Ala; C44A) strategies mimics the cellular and molecular phenotype of A457P hNET induced postural orthostatic intolerance syndrome (POTS). Palmitoylation of hNET is catalyzed by the ER‐bound DHHC1, resulting in increased total hNET expression suggesting a role in hNET ER‐golgi processing and maturation. By inhibiting palmitoylation through 2BP or point mutation, we demonstrated a rapid and marked reduction in total hNET expression, surface expression, and transport capacity, with prolonged inhibition resulting in a nearly identical cellular phenotype as A457P hNET. As the vast majority of NET‐based adrenergic disorders like POTS are idiopathic (not because of A457P), these findings provide insight into potentially novel avenues for the development of NET‐based adrenergic disorders. Postural orthostatic tachycardia syndrome (POTS) is an adrenergic signaling disorder characterized by excessive plasma norepinephrine, postural tachycardia, and syncope. The norepinephrine transporter (NET) modulates adrenergic homeostasis via the reuptake of extracellular catecholamines and is implicated in the pathogenesis of adrenergic and neurological disorders. In this study, we reveal NET is palmitoylated in male Sprague–Dawley rats and Lilly Laboratory Cell Porcine Kidney (LLC‐PK1) cells. S‐palmitoylation, or the addition of a 16‐carbon saturated fatty acid, is a reversible post‐translational modification responsible for the regulation of numerous biological mechanisms. We found that LLC‐PK1 NET is dynamically palmitoylated, and that inhibition with the palmitoyl acyltransferase (DHHC) inhibitor, 2‐bromopalmitate (2BP) results in decreased NET palmitoylation within 90 min of treatment. This result was followed closely by a reduction in transport capacity, cell surface, and total cellular NET expression after 120 min of treatment. Increasing 2BP concentrations and treatment time revealed a nearly complete loss of total NET protein. Co‐expression with individual DHHCs revealed a single DHHC enzyme, DHHC1, promoted wild‐type (WT) hNET palmitoylation and elevated NET protein levels. The POTS‐associated NET mutant, A457P, exhibits dramatically decreased transport capacity and cell surface levels which we have confirmed in the current study. In an attempt to recover A457P NET expression, we co‐expressed the A457P variant with DHHC1 to drive expression as seen with the WT protein but instead saw an increase in NET N‐terminal immuno‐detectable forms and fragments. Elimination of a potential palmitoylation site at cysteine 44 in the N‐terminal tail of hNET resulted in a low expression phenotype mimicking the A457P hNET variant. Further investigation of A457P NET palmitoylation and surface expression is necessary, but our preliminary novel findings reveal palmitoylation as a mechanism of NET regulation and suggest that dysregulation of this process may contribute to the pathogenesis of adrenergic disorders like POTS.

Palmitoylation regulates norepinephrine transporter uptake, surface localization, and total expression with pathogenic implications in postural orthostatic tachycardia syndrome

Palmitoylation regulates norepinephrine transporter trafficking and expression and is potentially involved in the pathogenesis of postural orthostatic tachycardia syndrome

Neurotensin receptor-1 inducible palmitoylation is required for efficient receptor-mediated mitogenic-signaling within structured membrane microdomains

Role of palmitoylation on the neuronal glycine transporter GlyT2

GW24-e3148 A RyR2-V1810L mutation identified in a Chinese patient with clinic manifestation of postural orthostatic tachycardia syndrome

Increased CRTH2 Expression in Postural Orthostatic Tachycardia Syndrome

Palmitoylation Regulates Human Serotonin Transporter Activity, Trafficking, and Expression and Is Modulated by Escitalopram

A functional cell-based bioassay for assessing adrenergic autoantibody activity in postural tachycardia syndrome

Altered Protein Palmitoylation as Disease Mechanism in Neurodegenerative Disorders

Clinical Features of Hyperadrenergic Postural Tachycardia Syndrome in Children.

De-palmitoylation by N-(tert-Butyl) hydroxylamine inhibits AMPAR-mediated synaptic transmission via affecting receptor distribution in postsynaptic densities

Neuropilin 1 sequestration by neuropathogenic mutant glycyl-tRNA synthetase is permissive to vascular homeostasis

Pathogenesis and Individualized Treatment for Postural Tachycardia Syndrome in Children

N-Palmitoyl glycine activates transient receptor potential channel 5 and increases the risk of Brugada syndrome

Physiological Stimuli Induce PAD4-Dependent, ROS-Independent NETosis, With Early and Late Events Controlled by Discrete Signaling Pathways

Clinical neurophysiology of postural tachycardia syndrome

Postural tachycardia syndrome: a heterogeneous and multifactorial disorder

Hyperadrenergic Postural Tachycardia Syndrome: Clinical Biomarkers and Response to Guanfacine

Pediatric Postural Orthostatic Tachycardia Syndrome: from Mechanisms to Individualized Management

Postural orthostatic tachycardia syndrome: clinical presentation, aetiology and management